Grove Ventures

Grove Ventures is a Tel Aviv early-stage deep-tech fund led by veteran Israeli operators, with a thesis that puts AI infrastructure, bio-convergence, and complex semiconductor technologies at the center of the investment scope. Healthcare appears in the portfolio when the underlying technology is genuinely deep, rather than as a standalone clinical software thesis. Physician founders working on bio-convergence, advanced imaging, or compute-intensive medical AI should treat Grove as a serious option.

The thesis rewards technical depth. Grove is comfortable with long development cycles, hard regulatory paths, and companies where the moat is built on novel science or engineering rather than on go-to-market speed. That orientation makes the fund a credible partner for medical-device companies with a deep-tech component, AI-driven diagnostics that require unusual compute or data architectures, and bio-convergence companies that sit at the intersection of life science and engineering. The fund does not publish a healthcare-specific portfolio carve-out, but the deep-tech lens is consistent across the book.

Check sizes run from 1 million to 5 million dollars at entry, with the fund operating across pre-seed, seed, and Series A. Grove will lead or co-lead, particularly at seed, and is comfortable being the first institutional investor in a technical team that has not yet built a commercial motion. Geography is Israel-centric, with the expectation that portfolio companies will scale internationally and engage United States and European customers as they mature.

The team is built around operators with deep technology and operating backgrounds, and Grove engages hands-on with portfolio companies on technical strategy, hiring, and architecture decisions. The partner group is small enough that founders work directly with the people who decide.

Approach Grove when you are a physician or scientist founder with a deep-tech thesis: a novel imaging modality, a bio-convergence platform, an AI tool that requires unusual data or compute, or a medical device with real engineering depth. Pure clinical-workflow software founders will find a better fit elsewhere. Warm introductions from Israeli technology operators, academic technology-transfer offices, or other deep-tech VCs are the most reliable path in. Time the conversation when you have a working prototype, a credible technical team, and a clear answer to the question of why your approach is genuinely hard for others to replicate. Pre-revenue is fine; the diligence will focus on the technology and the team.